AxoGen Aktie
WKN DE: A1JMHK / ISIN: US05463X1063
|
16.11.2026 23:00:03
|
AxoGen: 3 Key Takeaways for Long-Term Investors
On its third-quarter 2026 earnings call, held on Oct. 28, 2026, AxoGen (NASDAQ:AXGN) raised its full-year 2026 revenue guidance to at least $290 million. The company's nerve repair portfolio is gaining broader adoption across surgical specialties. Expanding health plan coverage helps secure its market position.
Management highlights three takeaways that drive this growth.
AxoGen acquired BioCircuit to add NerveTape, a sutureless device that connects severed nerves faster than traditional stitching, to its product line. This acquisition expands the addressable market into direct nerve repairs, which represent nearly half of all surgical nerve transection procedures.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AxoGen Inc.
|
27.10.26 |
Ausblick: AxoGen stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) | |
|
28.07.26 |
Ausblick: AxoGen stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net) |
Analysen zu AxoGen Inc.
Aktien in diesem Artikel
| AxoGen Inc. | 50,16 | -0,59% |
|